May 29 (Reuters) - Johnson & Johnson ( JNJ ) said on
Wednesday its experimental therapy, seltorexant, met all main
and secondary goals in a late-stage study evaluating it in
patients with major depressive disorder (MDD) and insomnia
symptoms.
The therapy was given as a supplemental treatment to
antidepressants in the study.